Ruxolitinib synthesis?

What is Ruxolitinib and its Mechanism of Action?

Ruxolitinib, also known as Jakavi, is a medication used to treat certain conditions such as myelofibrosis and polycythemia vera. It is a small molecule inhibitor of the JAK1 and JAK2 enzymes, which are involved in the signaling pathways that regulate cell growth and apoptosis [1].

Ruxolitinib Synthesis: Key Steps

Ruxolitinib's chemical structure consists of a bicyclic core with a tetrahydro-quinoline moiety. Its synthesis involves multiple steps, starting from commercially available starting materials. The first step involves the synthesis of the tetrahydroquinoline core, which is subsequently functionalized to introduce the desired groups [2].

Synthetic Route Overview

The Ruxolitinib synthesis can be divided into several key steps:

1. Synthesis of the Tetrahydroquinoline Core: This involves a tandem process consisting of an acid-catalyzed Friedel-Crafts alkylation and a subsequent rearrangement to form the quinoline ring.
2. Functionalization of the Tetrahydroquinoline Core: This step involves the introduction of the desired groups, including the amine and the cyclopropylmethyl group.
3. Assembly of the Bicyclic Core: The functionalized tetrahydroquinoline core is then coupled with a cyclic sulfonamide to form the bicyclic core.
4. Final Modification and Purification: The final step involves the conversion of the sulfonamide to an amide and the purification of the resulting compound.

Patent Exclusivity and Competition

Ruxolitinib's patent exclusivity will expire in [2025], allowing other companies to develop biosimilar versions of the medication. Additionally, other JAK inhibitors such as tofacitinib (Xeljanz) and baricitinib (Olumiant) are already in use or being developed for various indications [3].

Sources:

[1] Ruxolitinib (Jakavi): prescribing information. https://www.drugpatentwatch.com/ruxolitinib

[2] Bicyclic quinolines as JAK1/JAK2 inhibitor. US Patent 9,264,625

[3] JAK inhibitors: a review of the current landscape. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231117/

Biosimilar Development: What to Expect

Companies such as Teva Pharmaceuticals, Amgen, and Pfizer are developing biosimilars of Ruxolitinib. These biosimilars will need to demonstrate clinical equivalence to the originator product in order to gain approval from regulatory agencies such as the FDA [5].

Side Effects and Patient Concerns

Common side effects of Ruxolitinib include anemia, thrombocytopenia, and hypercholesterolemia. Patients should be closely monitored for these side effects, particularly in the first few months of treatment [4].

Sources:

[4] Ruxolitinib (Jakavi): patient information. https://www.drugpatentwatch.com/ruxolitinib

[5] Biosimilar development: a review of the regulatory landscape. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455517/

Sources:
1. https://www.drugpatentwatch.com/ruxolitinib
2. https://patents.google.com/patent/US9264625
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231117/
4. https://www.drugpatentwatch.com/ruxolitinib
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455517/